Atossa Therapeutics/ATOS

$1.44

6.67%
-
1D1W1MYTD1YMAX

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines in areas of unmet medical need in oncology with a focus on breast cancer. The Company’s lead drug candidate under development is oral (Z)-endoxifen, which the Company is developing in two settings: one to treat breast cancer by reducing tumor cell activity prior to surgery and another to reduce breast tissue density in women. Its programs under development include (Z)-endoxifen Programs, AT-H201, and other programs. (Z)-endoxifen is an active metabolite of tamoxifen, to treat and prevent breast cancer in high-risk women. It is developing a form of (Z)-endoxifen, which is administered orally for the potential treatment of breast cancer and reduction of breast density. AT-H201 is for lung injury caused by cancer treatments. AT-H201 consists of a combination of two drugs to treat other diseases. Its other programs include Immunotherapy/CAR-T Programs, which is in early stage of development.

Ticker

ATOS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Steven Quay

Employees

10

Headquarters

Seattle, United States

ATOS Metrics

BasicAdvanced
$192.97M
Market cap
-
P/E ratio
-$0.24
EPS
1.27
Beta
-
Dividend rate
$192.97M
1.27249
$2.31
$0.59
1.5M
17.612
-27.39%
-28.88%
-28.8%
2.12
2.12
-12.08%

What the Analysts think about ATOS

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
218.06% upside
High $5.75
Low $4.00
$1.44
Current price
$4.58
Average price target

ATOS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-7.7M
24.19%
Profit margin
0%
-

ATOS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 58.82%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.05
-$0.08
-$0.05
-$0.09
-
Expected
-$0.06
-$0.06
-$0.07
-$0.06
-$0.07
Surprise
-16.67%
33.33%
-28.57%
58.82%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Atossa Therapeutics stock?

Atossa Therapeutics (ATOS) has a market cap of $192.97M as of April 19, 2024.

What is the P/E ratio for Atossa Therapeutics stock?

The price to earnings (P/E) ratio for Atossa Therapeutics (ATOS) stock is 0 as of April 19, 2024.

Does Atossa Therapeutics stock pay dividends?

No, Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Atossa Therapeutics dividend payment date?

Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders.

What is the beta indicator for Atossa Therapeutics?

Atossa Therapeutics (ATOS) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Atossa Therapeutics stock price target?

The target price for Atossa Therapeutics (ATOS) stock is $4.58, which is 222.54% above the current price of $1.42. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Atossa Therapeutics stock

Buy or sell Atossa Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing